Giving a boost to its declining bottomline, the drug maker, Lupin is all set to launch the generic version of anti-HIV drug, Combivir in the USA. The said drug is the combination of lamividine and zidovudine tablets and is prescribed in combination with other antiretroviral agents for the treatment of HIV-1 infection. The company is waiting for final approval from US Food and Drug Administration (FDA).
Lupin is currently trading at Rs. 537.90, up by 21.40 points or 4.14% from its previous closing of Rs. 516.50 on the BSE.
The scrip opened at Rs. 518.00 and has touched a high and low of Rs. 540.00 and Rs. 515.80 respectively. So far 49963 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 574.05 on 17-Apr-2012 and a 52 week low of Rs. 404.55 on 13-May-2011.
Last one week high and low of the scrip stood at Rs. 559.50 and Rs. 507.70 respectively. The current market cap of the company is Rs. 24032.02 crore.
The promoters holding in the company stood at 46.93% while Institutions and Non-Institutions held 44.05% and 9.02% respectively.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: